WEBULL
News
FBRX
32.11
+4.32%
1.33
Forte Biosciences CEO to Present at Guggenheim Biotech Summit
Reuters · 5d ago
Forte Biosciences präsentiert auf Investorenkonferenzen in New York, Boston und Miami
Reuters · 5d ago
Weekly Report: what happened at FBRX last week (0202-0206)?
Weekly Report · 5d ago
Weekly Report: what happened at FBRX last week (0126-0130)?
Weekly Report · 02/02 10:34
Weekly Report: what happened at FBRX last week (0119-0123)?
Weekly Report · 01/26 10:34
Weekly Report: what happened at FBRX last week (0112-0116)?
Weekly Report · 01/19 10:41
Weekly Report: what happened at FBRX last week (0105-0109)?
Weekly Report · 01/12 10:40
Weekly Report: what happened at FBRX last week (1229-0102)?
Weekly Report · 01/05 10:33
After-Hours Gainers: GH Research, Phathom, Forte, OKYO, Zai Lab, LifeMD, Werewolf & Corvus Rally
NASDAQ · 01/05 03:16
Top Executive Makes Bold Insider Move on Forte Biosciences Stock
TipRanks · 01/03 02:03
Forte Biosciences CFO Antony A. Riley Acquires Common Shares
Reuters · 01/02 21:05
Weekly Report: what happened at FBRX last week (1222-1226)?
Weekly Report · 12/29/2025 10:32
Forte Biosciences Grants 75,000 Stock Options to New Employee as Inducement Award
Reuters · 12/22/2025 21:01
FORTE BIOSCIENCES, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULES
Reuters · 12/22/2025 21:01
Weekly Report: what happened at FBRX last week (1215-1219)?
Weekly Report · 12/22/2025 10:32
Evercore ISI Remains a Buy on Forte Biosciences (FBRX)
TipRanks · 12/18/2025 15:25
Weekly Report: what happened at FBRX last week (1208-1212)?
Weekly Report · 12/15/2025 10:40
Weekly Report: what happened at FBRX last week (1201-1205)?
Weekly Report · 12/08/2025 10:39
Weekly Report: what happened at FBRX last week (1124-1128)?
Weekly Report · 12/01/2025 10:34
Forte Biosciences Price Target Announced at $65.00/Share by Evercore ISI Group
Dow Jones · 11/25/2025 13:07
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.